Cargando…

2136. In Vitro Activity of Nacubactam (OP0595) Combined with Cefepime against Carbapenem-resistant Enterobacterales Isolated in Japan

BACKGROUND: Nacubactam is a new non-β-lactam diazabicyclooctane β-lactamase inhibitor that inhibits penicillin binding protein 2 (PBP2) of Enterobacterales and acts synergistically as a β-lactam enhancer when combined with β-lactams. Nacubactam is under development for the treatment of serious Gram-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yanagihara, Katsunori, Mikamo, Hiroshige, Tateda, Kazuhiro, Doi, Yohei, Ohge, Hiroki, Takahashi, Satoshi, Kondo, Kenichiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678573/ http://dx.doi.org/10.1093/ofid/ofad500.1759

Ejemplares similares

1279. In Vitro Activity of Nacubactam (OP0595) Alone and in Combination with β-Lactams against β-Lactamase-Producing Enterobacterales Isolated in Japan
por: Nagira, Yu, et al.
Publicado: (2020)

In Vivo Pharmacodynamics of β-Lactams/Nacubactam against Carbapenem-Resistant and/or Carbapenemase-Producing Enterobacter cloacae and Klebsiella pneumoniae in Murine Pneumonia Model
por: Hagihara, Mao, et al.
Publicado: (2021)

647. Cefepime Versus Carbapenems for the Treatment of ESBL-producing Enterobacterales among Non-blood Isolates
por: Garcia, Brandon, et al.
Publicado: (2022)

1287. Pharmacokinetics, Safety, and Tolerability of Nacubactam after Single Coadministration with β-Lactams in Japanese Healthy Subjects
por: Asano, Masayo, et al.
Publicado: (2020)

In Vitro Activity of Two Cefepime-Based Novel Combinations, Cefepime/Taniborbactam and Cefepime/Zidebactam, against Carbapenemase-Expressing Enterobacterales Collected in India
por: Bakthavatchalam, Yamuna Devi, et al.
Publicado: (2023)

2136 Frequently overlooked challenges of pragmatic trials
por: Kessler, Rodger S.
Publicado: (2018)

Re-evaluation of cefepime or piperacillin/tazobactam to decrease use of carbapenems in ESBL-producing Enterobacterales urinary tract infections (REDUCE-UTI)
por: Branton, Alexander C, et al.
Publicado: (2023)

628. Pharmacokinetics, Safety and Tolerability of Co-administration of Nacubactam and β-lactams after Multiple Doses in Japanese Healthy Subjects
por: Sato, Hiroki, et al.
Publicado: (2021)

1576. Re-Evaluation of cefepime or piperacillin-tazobactam to Decrease Use of Carbapenems in ESBL-Producing Enterobacterales BloodStream Infections (REDUCE-BSI)
por: Vu, Catherine H, et al.
Publicado: (2020)

1257. Re-Evaluation of Cefepime or Piperacillin-Tazobactam to Decrease Use of Carbapenems in ESBL-Producing Enterobacterales Urinary Tract Infections (REDUCE-UTI)
por: Branton, Alexander C, et al.
Publicado: (2021)

698. Nacubactam Inhibits Class A β-lactamases
por: Barnes, Melissa D, et al.
Publicado: (2018)

Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase–producing Enterobacterales bloodstream infections (REDUCE-BSI)
por: Vu, Catherine H., et al.
Publicado: (2022)

High-dose Cefepime vs Carbapenems for Bacteremia Caused by Enterobacterales With Moderate to High Risk of Clinically Significant AmpC β-lactamase Production
por: Kunz Coyne, Ashlan J, et al.
Publicado: (2023)

2150. In Vitro Activity of Cefepime-Taniborbactam and Comparators Against Genotypically Characterized Carbapenem-Resistant Enterobacterales (CRE) and Carbapenem-Resistant Pseudomonas aeruginosa (CRPA) from the United States, 2018-2021
por: Wise, Mark G, et al.
Publicado: (2023)

0595. Quantitating granulocyte reactive oxygen species production by flow cytometry in a clinical setting
por: Smit, B, et al.
Publicado: (2014)

Molecular characterization of clinical carbapenem-resistant Enterobacterales from Qatar
por: Abid, Fatma Ben, et al.
Publicado: (2021)

1374. Carbapenem-Resistant Enterobacterales Infection in Children: Clinical and Molecular Data from a Prospective Multicenter Cohort Study
por: Fisher, Matthew, et al.
Publicado: (2020)

In vivo pharmacokinetic/pharmacodynamic evaluation of cefepime/taniborbactam combination against cefepime-non-susceptible Enterobacterales and Pseudomonas aeruginosa in a murine pneumonia model
por: Abdelraouf, Kamilia, et al.
Publicado: (2023)

1029. Increased Mortality in Hospital-Onset Carbapenem-Resistant Enterobacterales Bloodstream Infections
por: Boutzoukas, Angelique E, et al.
Publicado: (2023)

In Vitro Efficacy of Antibiotic Combinations with Carbapenems and Other Agents against Anaerobic Bacteria
por: Umemura, Takumi, et al.
Publicado: (2022)

2775. Clinical Outcomes and Treatment-Emergent Resistance of Piperacillin-tazobactam, Cefepime, Carbapenems and Fluoroquinolones for the Treatment of Bloodstream Infections due to AmpC β-Lactamase-Producing Enterobacterales
por: Jawanda, Jasanjeet, et al.
Publicado: (2023)

2136: Gut microbiome alterations in children undergoing hematopoietic stem cell transplantation
por: Qayed, Muna, et al.
Publicado: (2018)

878. Antimicrobial Susceptibility of Pathogens Isolated from Surgical Site Infections in Japan: Comparison of Data from Nationwide Surveillance Studies Conducted in 2010, 2014–2015 and 2018-2019
por: Takesue, Yoshio, et al.
Publicado: (2020)

133. ARGONAUT-III: Susceptibility of Carbapenem-resistant Klebsiellae to Cefepime-Taniborbactam
por: Mack, Andrew R, et al.
Publicado: (2021)

Activity of mecillinam against carbapenem-resistant Enterobacterales
por: Emeraud, Cécile, et al.
Publicado: (2022)

Updates on the Status of Carbapenem-Resistant Enterobacterales in Lebanon
por: Fadlallah, Mahdi, et al.
Publicado: (2023)

593. Evaluation of the EDTA-modified Carbapenem Inactivation Method (eCIM) with Using the EDTA Blood Collection Tube for Differentiating the Serine- and Metallo-β-lactamase (MBL) Producing Enterobacterales
por: Sakanashi, Daisuke, et al.
Publicado: (2023)

2136. Rapid Antimicrobial Susceptibility Testing using ATP Luminescence and Machine Learning Methods
por: Kawabe, Shunsuke, et al.
Publicado: (2019)

Screening for Metallo-Beta-Lactamases Using Non-Carbapenem Agents: Effective Detection of MBL-Producing Enterobacterales and Differentiation of Carbapenem-Resistant Enterobacterales
por: Takei, Kentarou, et al.
Publicado: (2023)

An Overview on Phenotypic and Genotypic Characterisation of Carbapenem-Resistant Enterobacterales
por: Rabaan, Ali A., et al.
Publicado: (2022)

The fecal carriage rate of extended-spectrum β-lactamase–producing or carbapenem-resistant Enterobacterales among Japanese infants in the community at the 4-month health examination in a rural city
por: Kawata, Soichiro, et al.
Publicado: (2023)

The carbapenem inoculum effect provides insight into the molecular mechanisms underlying carbapenem resistance in Enterobacterales
por: Cartagena, Alexis Jaramillo, et al.
Publicado: (2023)

160. Antimicrobial Prescribing Patterns in Bloodstream Infections Caused by Cefepime-Susceptible Extended Spectrum β-lactamase Enterobacterales
por: O’Rourke, Emerald, et al.
Publicado: (2022)

Nucleotide binding as an allosteric regulatory mechanism for Akkermansia muciniphila β-N-acetylhexosaminidase Am2136
por: Li, Chang-Cheng, et al.
Publicado: (2022)

2789. Cefepime Versus Non-Cefepime/Non-Carbapenem Therapy for Blood Stream Infections Caused by Non-ESBL-Producing Serratia Marcescens: A Subgroup Analysis of The Carbapenem-Serratia Multicenter Retrospective Cohort Study
por: Mughrabi, Abdallah, et al.
Publicado: (2023)

Molecular epidemiology of carbapenem-resistant Enterobacterales in Thailand, 2016–2018
por: Paveenkittiporn, Wantana, et al.
Publicado: (2021)

Poor outcomes in both infection and colonization with carbapenem-resistant Enterobacterales
por: Howard-Anderson, Jessica R., et al.
Publicado: (2022)

Molecular epidemiology and outcome of carbapenem-resistant Enterobacterales in Saudi Arabia
por: Alraddadi, Basem M., et al.
Publicado: (2022)

Monitoring Carbapenem-Resistant Enterobacterales in the Environment to Assess the Spread in the Community
por: Urase, Taro, et al.
Publicado: (2022)

Early Years of Carbapenem-Resistant Enterobacterales Epidemic in Abu Dhabi
por: Pál, Tibor, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3l5foq95iqsm698tu9u8gq8qsp